Mark Bustard

Mark took over as IBioIC’s CEO in February 2020. He originally joined the Centre in 2019 as Commercial Director, where he led the commercial strategy in identifying and securing opportunities IBioIC to engage, collaborate with and support large corporates, SMEs, academia and Government to accelerate and de-risk commercialisation, and to bring new biotechnology processes and products to the global market.

Mark’s career has been focused on medicines, healthcare and biologics development and he has held senior positions at CPI where he was Business Development Director for the National Biologics Manufacturing Centre in Darlington, and KTN, where he was the Medicines Manufacturing Specialist and Technical Director for Medicines at the previous HealthTech and Medicines KTN.